Actin vs Vytora Health
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Actin
Best for affordable compounded semaglutide with B12 enhancementStarting at $133/mo
Vytora Health
Best for Patients seeking month-to-month or 3-month-bundle compounded semaglutide or tirzepatide with the option of brand-name Mounjaro/Zepbound on a single LegitScript-approved + HIPAA-compliant platform with named pharmacy partners and transparent operating-PC disclosure. Particularly suited for patients in KS, LA, MS, NM, WV where Vytora's audio-visit option satisfies state telehealth compliance.Starting at $150/mo
Side-by-Side Comparison
| Feature | Actin | Vytora Health |
|---|---|---|
| Overall Score | 7.0/10 | ✓8.7/10 |
| Starting Price | ✓$133/mo | $150/mo |
| Editorial Rating | 3.5 ★ /5 | ✓4.4 ★ /5 |
| Features | 2 features | ✓10 features |
| States Available | 0 | ✓51 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | ✓ Yes |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Actin
Pros
- ✓Semaglutide + B12 combination for added energy support
- ✓Transparent pricing — exact cost shown upfront with no hidden fees
- ✓Competitive starting price from $133
Cons
- ✗Semaglutide only — no tirzepatide or liraglutide
- ✗No visible LegitScript or PCAB accreditation
- ✗State availability not disclosed
- ✗Broader platform (hormones, sexual wellness, hair health)
Vytora Health
Pros
- ✓All 50 states + DC coverage with explicit per-state-modality compliance (video vs audio) disclosure
- ✓Both compounded AND brand-name options on a single platform — uncommon (most compounded-focused providers do not offer brand)
- ✓LegitScript Approved + HIPAA Compliant — both disclosed primary-source-verifiable
- ✓Pharmacy partners named publicly: Vials Pharmacy (TX) + Greenwich Biosciences — uncommon transparency
- ✓Owner / operating PC disclosed: Wasef Health, PC (Pinellas Park, FL)
- ✓Month-to-month pricing competitive ($180 sema / $249 tirz) and 3-month bundle (17% discount) for cost-sensitive patients
- ✓Brand-name Mounjaro and Zepbound available for patients who can self-pay $1,399/mo for FDA-approved options
- ✓Adjunct peptide offerings (NAD+, Sermorelin) for patients pursuing broader optimization regimens
Cons
- ✗Brand-name Mounjaro/Zepbound pricing ($1,399/mo) is near-retail; insured patients should pursue PA through traditional pharmacy + LillyDirect Self Pay Journey Program ($449-$699/mo) for better economics
- ✗Compounded tirzepatide tier ($249/mo) is above the lowest market floor ($149-199/mo) — Vytora pricing is mid-market for compounded
- ✗Specific dose-tier pricing not publicly broken out — pricing shown as 'all doses included' which is favorable but means high-dose patients pay the same as low-dose patients
- ✗Initial consultation cost not disclosed on public-facing pricing page (some providers free, some $99)
- ✗Limited primary-source-verifiable state licensure detail per individual prescriber (most multi-state telehealth platforms have this gap)
Our Verdict
Vytora Health edges out Actin with a higher overall score of 8.7/10 and is particularly strong for Patients seeking month-to-month or 3-month-bundle compounded semaglutide or tirzepatide with the option of brand-name Mounjaro/Zepbound on a single LegitScript-approved + HIPAA-compliant platform with named pharmacy partners and transparent operating-PC disclosure. Particularly suited for patients in KS, LA, MS, NM, WV where Vytora's audio-visit option satisfies state telehealth compliance.. Actin remains a solid alternative, especially if you're looking for affordable compounded semaglutide with B12 enhancement.
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.